Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Rhea-AI Summary

Carisma Therapeutics reported Q3 2024 financial results with cash and cash equivalents of $26.9 million, expected to fund operations into Q3 2025. Research and development expenses decreased to $11.3 million from $19.6 million year-over-year. The company anticipates initial results from the Phase 1 study of CT-0525 in Q1 2025 and plans to nominate a development candidate for its liver fibrosis program in the same quarter. New preclinical data for anti-GPC3 CAR-M therapy and liver fibrosis will be presented at upcoming scientific meetings. The company recently expanded its collaboration with Moderna to include autoimmune disease targets.

Positive

• Cash position of $26.9M expected to fund operations into Q3 2025
• R&D expenses decreased by $8.3M year-over-year
• G&A expenses reduced by $1.4M compared to previous year
• Net loss decreased to $12.7M from $21.4M in Q3 2023
• Expanded collaboration with Moderna for autoimmune disease targets

Negative

• Cash decreased from $40.4M in Q2 2024 to $26.9M in Q3 2024
• Halted development of CT-0508 and paused CT-1119 development
• Implemented workforce reduction as part of revised operating plan

Insights

Financial Analyst

A critical analysis of Carisma's Q3 financials reveals concerning trends despite operational streamlining. The $26.9M cash position represents a significant $13.5M burn from $40.4M in Q2, though R&D expenses decreased by 42.3% to $11.3M. The runway extension into Q3 2025 appears tight given the current burn rate and multiple clinical programs.

Key positives include reduced operating expenses through strategic program cuts and the expanded Moderna collaboration. However, investors should note that the company will likely need additional funding before reaching significant clinical milestones in 2025. The operational restructuring has helped, with G&A expenses down 21.2%, but sustainable financing remains a critical challenge.

Medical Research Analyst

The clinical development strategy shows promising focus with CT-0525's protocol amendment introducing multiple dosing regimens. The expansion to include combination therapy with pembrolizumab and various dosing schedules demonstrates clinical sophistication. However, the timeline for initial data from Cohorts 1 and 2 in Q1 2025 coincides with dwindling cash reserves.

The GPC3+ solid tumor program and liver fibrosis candidate nominations represent potential value drivers, but their early stage nature means significant development costs lie ahead. The autoimmune disease collaboration with Moderna provides strategic validation but may not translate to near-term financial relief.

Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025

Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025

New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy to be presented on November 8 at SITC 2024 Annual Meeting

New preclinical efficacy data in liver fibrosis to be presented on November 17 at AASLD - The Liver Meeting ^® 2024

Cash and cash equivalents of $26.9 million expected to fund the Company into the third quarter of 2025

PHILADELPHIA, Nov. 7, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2024, and highlighted recent business updates.

"Our recent progress across clinical and preclinical programs demonstrates our commitment to pioneering therapies that address significant unmet medical needs," said Steven Kelly, President and CEO of Carisma Therapeutics. "We are advancing on multiple fronts. We expect to report initial data from the Phase 1 study of CT-0525 in the first quarter of 2025. We also recently nominated our first development candidate in hepatocellular carcinoma with Moderna and are excited to bring additional in vivo CAR-M therapies forward, including autoimmune targets. Our liver fibrosis program is progressing as well, with the nomination of a development candidate anticipated in the first quarter of 2025. These key milestones move us closer to delivering transformative treatments for patients in need."

Third Quarter 2024 Highlights and Upcoming Milestones

Ex Vivo Oncology

• CT-0525 (Anti-HER2 chimeric antigen receptor monocyte (CAR-Monocyte))
  • On November 5, 2024, Carisma announced the upcoming presentation of a trial in progress (TIP) poster for its Phase 1 clinical trial evaluating CT-0525, an autologous CAR-Monocyte therapy for the treatment of HER2+ solid tumors. The poster will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, Texas, on November 8, 2024.
  • In September 2024, Carisma submitted a protocol amendment for its Phase 1 study of CT-0525 to allow for the expansion of the study to include repeat dosing (up to two billion CAR positive cells administered every three weeks for up to five cycles) in combination with pembrolizumab, bolus dosing (up to10 billion CAR positive cells in a single dose) in combination with pembrolizumab, or either of these two dosing schedules as monotherapy (without checkpoint inhibitor). Repeat dosing in combination with pembrolizumab will be prioritized and the other three study arms may be activated as data indicates.
  • Carisma expects to report initial data for Cohorts 1 and 2 of its Phase 1 study of CT-0525 in the first quarter of 2025.

In Vivo Program (Moderna Collaboration)

• Autoimmune disease (CAR-M + mRNA/LNP)
  • On September 10, 2024, Carisma announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte ("CAR-M") collaboration with Moderna, Inc. ("Moderna") to include the nomination of two research targets for the treatment of autoimmune diseases. Carisma retains all rights in autoimmune disease beyond the two nominated targets, which will be exclusively partnered with Moderna.
• GPC3+ solid tumors (CAR-M + mRNA/LNP)
  • On November 5, 2024, Carisma announced the upcoming presentation of new pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for the treatment of hepatocellular carcinoma (HCC), developed in collaboration with Moderna. These data will be presented in a poster session at the SITC Annual Meeting in Houston, Texas, on November 8, 2024. These preclinical data demonstrate robust anti-tumor activity and introduce a novel, off-the-shelf approach for GPC3+ solid tumors.

Fibrosis

• • On August 6, 2024, Carisma announced that new preclinical data for liver fibrosis will be highlighted in a poster presentation at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting^® 2024, to be held November 15 through 19, 2024, in San Diego, California.
  • Carisma expects to nominate a development candidate for its liver fibrosis program in the first quarter of 2025.

Corporate Update

• On October 30, 2024, Carisma announced the appointment of Sohanya Cheng to the Board of Directors of the Company, effective October 31, 2024. Ms. Cheng brings over 20 years of experience in biopharmaceutical commercialization and research, with a strong focus on oncology. The Company concurrently announced the resignation of Michael Torok from Carisma's Board of Directors, also effective October 31, 2024.

Third Quarter 2024 Financial Results

• Cash and cash equivalents as of September 30, 2024, were $26.9 million, compared to $40.4 million as of June 30, 2024.
• Research and development expenses for the three months ended September 30, 2024 were $11.3 million, compared to $19.6 million for the three months ended September 30, 2023. The decrease of $8.3 million was primarily due to implementation of our revised operating plan in the second quarter of 2024 in which we halted further development of CT-0508, paused development of CT-1119 and implemented a workforce reduction. As result of the revised operating plan, we experienced a decrease of $2.4 million related to halting development of CT-0508 and a $0.1 million decrease from pausing the development of CT-1119. In addition, the implementation of the revised operating plan resulted in a decrease in facilities and other expenses of $3.1 million due to less laboratory supplies and laboratory space needs and a $0.9 million decrease in direct personnel costs due to a reduction in headcount. Further, we experienced a $0.9 million decrease in direct costs associated with pre-clinical development of CT-0525 due to the timing of the development program and a decrease of $0.9 million in other clinical and pre-clinical development expenses resulting from the timing of certain studies in our in vivo collaboration with Moderna.
• General and administrative expenses for the three months ended September 30, 2024 were $5.2 million, compared to $6.6 million for the three months ended September 30, 2023. The decrease of $1.4 million was primarily due to our revised operating plan in which we recognized a $1.3 million decrease in professional fees as a result of our patent portfolio and expanding infrastructure in 2023, a $0.3 million decrease in facilities and supplies due to a decrease in office expenditures, a $0.2 million decrease in insurance costs, and a $0.1 million decrease in other expenses related to a decline in travel costs, partially offset by a $0.5 million increase in personnel costs driven by an increase in stock-based compensation.
• Net loss was $12.7 million for the third quarter of 2024, compared to a $21.4 million net loss for the same period in 2023.

Outlook

Carisma anticipates that its cash and cash equivalents of $26.9 million as of September 30, 2024 are sufficient to sustain its planned operations into the third quarter of 2025. The Company's cash forecast contains estimates and assumptions, and management cannot predict the timing of all cash receipts and expenditures with certainty. Variances from management's estimates and assumptions could impact the Company's liquidity prior to the third quarter of 2025.

About CT-0525

CT-0525 is a first-in-class, ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). It is being studied in a multi-center, open label, Phase 1 clinical trial for patients with advanced/metastatic HER2-overexpressing solid tumors that have progressed on available therapies. The CAR-Monocyte approach has the potential to address some of the challenges of treating solid tumors with cell therapies, including tumor infiltration, immunosuppression within the tumor microenvironment, and antigen heterogeneity. CT-0525 has the potential to enable significant dose escalation, enhance tumor infiltration, increase persistence, and reduce manufacturing time compared to macrophage therapy.

About Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

Cautionary Note on Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, (i) Carisma's ability to realize the anticipated benefits of its pipeline reprioritization and corporate restructuring, (ii) Carisma's ability to obtain, maintain and protect its intellectual property rights related to its product candidates; (iii) Carisma's ability to advance the development of its product candidates under the timelines it anticipates in planned and future clinical trials and with its current financial and human resources; (iv) Carisma's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; (v) Carisma's ability to realize the anticipated benefits of its research and development programs, strategic partnerships, research and licensing programs and academic and other collaborations; (vi) regulatory requirements or developments and Carisma's ability to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities related to its product candidates; (vii) changes to clinical trial designs and regulatory pathways; (viii) risks associated with Carisma's ability to manage expenses; (ix) changes in capital resource requirements; (x) risks related to the inability of Carisma to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; and (xi) legislative, regulatory, political and economic developments.

For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's other recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this press release speak as of the date of this press release. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com

Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com

CARISMA THERAPEUTICS INC. Unaudited Consolidated Balance Sheets (in thousands, except share and par value)
	September 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$           26,881		$           77,605
Prepaid expenses and other assets	7,256		2,866
Total current assets	34,137		80,471
Property and equipment, net	5,391		6,764
Right of use assets – operating leases	2,322		2,173
Deferred financing costs	208		146
Total assets	$           42,058		$           89,554
Liabilities and Stockholders' (Deficit) Equity
Current liabilities:
Accounts payable	$              1,728		$              3,933
Accrued expenses	4,542		7,662
Deferred revenue	682		1,413
Operating lease liabilities	1,386		1,391
Finance lease liabilities	1,074		544
Other current liabilities	1,146		965
Total current liabilities	10,558		15,908
Deferred revenue	41,250		45,000
Operating lease liabilities	761		860
Finance lease liabilities	96		328
Other long-term liabilities	519		926
Total liabilities	53,184		63,022
Stockholders' (deficit) equity:
Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding	—		—
Common stock $0.001 par value, 350,000,000 shares authorized, 41,750,109 and 40,609,915 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	41		40
Additional paid-in capital	276,777		271,594
Accumulated deficit	(287,944)		(245,102)
Total stockholders' (deficit) equity	(11,126)		26,532
Total liabilities and stockholders' (deficit) equity	$           42,058		$           89,554

 

CARISMA THERAPEUTICS INC. Unaudited Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data)
	Three Months Ended September 30,
	2024		2023
Collaboration revenues	$              3,385		$              3,827
Operating expenses:
Research and development	11,326		19,551
General and administrative	5,203		6,620
Total operating expenses	16,529		26,171
Operating loss	(13,144)		(22,344)
Change in fair value of derivative liability	—		—
Interest income, net	442		941
Pre-tax loss	(12,702)		(21,403)
Income tax expense	—		—
Net loss	$          (12,702)		$          (21,403)
Share information:
Net loss per share of common stock, basic and diluted	$              (0.31)		$              (0.53)
Weighted-average shares of common stock outstanding, basic and diluted	41,588,035		40,285,858
Comprehensive loss
Net loss	$          (12,702)		$          (21,403)
Unrealized gain on marketable securities	—		108
Comprehensive loss	$          (12,702)		$          (21,295)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-reports-third-quarter-2024-financial-results-and-recent-business-highlights-302298111.html

SOURCE Carisma Therapeutics Inc.

FAQ

When will Carisma Therapeutics (CARM) report initial Phase 1 results for CT-0525?

Carisma Therapeutics expects to report initial data from Cohorts 1 and 2 of the Phase 1 study of CT-0525 in the first quarter of 2025.

What was Carisma Therapeutics' (CARM) cash position in Q3 2024?

Carisma Therapeutics reported cash and cash equivalents of $26.9 million as of September 30, 2024.

How long will Carisma Therapeutics' (CARM) current cash runway last?

The company's current cash position is expected to fund operations into the third quarter of 2025.

What was Carisma Therapeutics' (CARM) net loss in Q3 2024?

Carisma Therapeutics reported a net loss of $12.7 million for the third quarter of 2024.